{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:16:52Z","timestamp":1789697812939,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T00:00:00Z","timestamp":1446508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.clbc.2015.10.005","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T22:02:00Z","timestamp":1447106520000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)"],"prefix":"10.1016","volume":"16","author":[{"given":"Henry L.","family":"G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Neciosup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-5862","authenticated-orcid":false,"given":"C\u00e9lia","family":"Tosello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Bines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Ismael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia X.","family":"Santi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lio","family":"Pinczowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeni","family":"Ner\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Lerzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Cap\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Zarba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Blajman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirta S.","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-4506","authenticated-orcid":false,"given":"Jeovany","family":"Mart\u00ednez-Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-105X","authenticated-orcid":false,"given":"Gustavo","family":"Werutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2015.10.005_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2015.10.005_bib3","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2015.10.005_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2015.10.005_bib5","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.10.005_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2015.10.005_bib7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2015.10.005_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/tbj.12071","article-title":"A\u00a0systematic review of vinorelbine for the treatment of breast cancer","volume":"19","author":"Xu","year":"2013","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2015.10.005_bib9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/bjc.2011.591","article-title":"Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2","volume":"106","author":"Brain","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/ajco.12292","article-title":"Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer","volume":"10","author":"Chan","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clbc.2015.10.005_bib11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.breast.2013.07.048","article-title":"Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial","volume":"22","author":"Saip","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2015.10.005_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10549-013-2828-z","article-title":"A\u00a0phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer","volume":"143","author":"Janni","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 5","key":"10.1016\/j.clbc.2015.10.005_bib13","doi-asserted-by":"crossref","first-page":"v169","DOI":"10.1093\/annonc\/mdj975","article-title":"Gemcitabine: monochemotherapy of breast cancer","volume":"17","author":"Ferrazzi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2015.10.005_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3816\/CBC.2009.n.029","article-title":"Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer","volume":"9","author":"Yardley","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3816\/CBC.2004.n.019","article-title":"Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer","volume":"5","author":"O'Shaughnessy","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3747\/co.v17i2.422","article-title":"One year of complete clinical response in a metastatic breast cancer patient treated with a combination of lapatinib and gemcitabine","volume":"17","author":"Gasent Blesa","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2015.10.005_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5732\/cjc.010.10507","article-title":"Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients","volume":"30","author":"Xu","year":"2011","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ejca.2015.01.059","article-title":"Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"51","author":"Lorenzen","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib20","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.ejca.2013.07.142","article-title":"A\u00a0phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer","volume":"49","author":"Martin","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-011-1749-y","article-title":"Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer","volume":"131","author":"Gajria","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2015.10.005_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/1471-2407-12-322","article-title":"Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea","volume":"12","author":"Ro","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study","volume":"29","author":"Andersson","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.10.005_bib24","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","article-title":"Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study","volume":"110","author":"Burstein","year":"2007","journal-title":"Cancer"},{"issue":"suppl 3","key":"10.1016\/j.clbc.2015.10.005_bib25","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.3816\/CBC.2004.s.005","article-title":"Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2\/neu","volume":"4","author":"Stein","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2015.10.005_bib26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2015.10.005_bib27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2015.10.005_bib28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","article-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Giordano","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820915002438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820915002438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:24Z","timestamp":1761513264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820915002438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1526820915002438"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2015.10.005","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2015.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}